beta
Trial Radar AI
Clinical Trial NCT06366399 for Diabetes Mellitus, Type 2, Insulin Resistance, Glucose Intolerance, Sleep Disturbance, Overweight or Obesity, Insulin Sensitivity is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View
Back to Search

The Acute T-Rex (Timing of Resistance Exercise) Study

Recruiting
Clinical Trial NCT06366399 is an interventional study for Diabetes Mellitus, Type 2, Insulin Resistance, Glucose Intolerance, Sleep Disturbance, Overweight or Obesity, Insulin Sensitivity that is recruiting. It started on November 15, 2023 with plans to enroll 20 participants. Led by University of Utah, it is expected to complete by December 31, 2025. The latest data from ClinicalTrials.gov was last updated on April 3, 2025.
Brief Summary
The primary aim of this study is to evaluate if a single bout of AM vs PM resistance exercise has different effects on insulin sensitivity and sleep. A randomized cross-over trial be used to compare resistance exercise at two different times of the day. Each condition will take place in a laboratory setting. Each condition will consist of exercise, overnight sleep, and oral glucose tolerance tests the following day. The AM exercise will occur ~1.5 hours after habitual wake, and PM exercise will occur ~11 hours after habitual wake. After a 2-6 week washout, participants will complete the other condition. The hypothesis is that PM exercise will be more beneficial than AM exercise in improving insulin sensitivity. This study could identify if there is a better time of day to perform resistance exercise to decrease risk of developing Type 2 Diabetes Mellitus.
Official Title

Timing (AM v PM) of Acute Resistance Exercise on Glycemic Control in Older Adults: The Acute T-Rex Study

Conditions
Diabetes Mellitus, TYPE 2Insulin ResistanceGlucose IntoleranceSleep DisturbanceOverweight or ObesityInsulin Sensitivity
Other Study IDs
  • 00156659
NCT ID Number
NCT06366399
Start Date (Actual)
2023-11-15
Last Update Posted
2025-04-03
Completion Date (Estimated)
2025-12-31
Enrollment (Estimated)
20
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
Resistance Exercise
Strength-training
Sleep
Circadian Rhythm
Primary Purpose
Prevention
Design Allocation
Randomized
Interventional Model
Crossover Assignment
Masking
Double
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalAM Resistance Exercise
Resistance Exercise intervention taking place in the AM
Resistance Exercise Timing
1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
ExperimentalPM Resistance Exercise
Resistance Exercise intervention taking place in the PM
Resistance Exercise Timing
1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Insulin sensitivity
Insulin sensitivity will be calculated using the Matsuda Insulin Sensitivity Index
1 day
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Sleep Duration
Sum of time spent in stage 1, stage 2, stage 3 and rapid eye movement stage (REM) as assessed via polysomnography.
1 day
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
50 Years
Eligible Sexes
All
  • Men and women, all ethnicities, aged 50-74 years
  • BMI ≥25 kg/m² and <45 kg/m²
  • Weight stable (less than 5% change in the past 6 months)
  • Generally healthy individuals
  • Not meeting recommended activity guidelines for aerobic or resistance exercise

  • Uncontrolled cardiovascular, metabolic, renal, or pulmonary disease
  • Cancer treatment in the past 5 years
  • Untreated thyroid disease or other medical conditions affecting weight or energy metabolism
  • Current use of weight loss medication or other medications likely to impact energy balance
  • Bariatric surgery or extensive bowel resection in the past 2 years
  • Current or recent history (past 2 years) of eating disorder
  • Diagnosis of insomnia, sleep apnea, or other sleep and circadian disorders
  • Non-English speaking
  • HbA1c >6.5%
University of Utah logoUniversity of Utah306 active trials to explore
Study Central Contact
Contact: Tanya M Halliday, PhD, 801-213-1364, [email protected]
Contact: Study Email Study Email, 8014487897, [email protected]
1 Study Locations in 1 Countries

Utah

University of Utah HPER E Buildling, Salt Lake City, Utah, 84112, United States
Jason V Thomas, MS, Contact, [email protected]
Tanya M Halliday, PhD, Principal Investigator
Recruiting